Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation

BackgroundAlthough obesity-related type 2 diabetes mellitus (T2DM) and sarcopenia in the elderly have been increasing worldwide, the associations among visceral fat accumulation, skeletal muscle indices (mass, strength, and quality) and cardiovascular diseases in T2DM remain poorly investigated.MethodsWe enrolled 183 Japanese T2DM inpatients (126 men, 57 women; mean age 64.7 ± 12.6 years, ± SD). The estimated-visceral fat area (eVFA) and skeletal muscle mass were measured by each device using bioelectrical impedance analysis method. We also measured grip strength by dynamometer and motor nerve conduction velocity (MCV). We analyzed the difference in skeletal muscle indices between T2DM patients with and without visceral fat accumulation, and examined the impact of skeletal muscle indices on cardiovascular diseases in patients with visceral fat accumulation.ResultsThe prevalence of sarcopenia defined by the Consensus of Asian Working Group for Sarcopenia and low skeletal muscle mass were both lower in the visceral fat accumulation (+) group than in (−) group. However, the prevalence of weak hand grip strength was similar in the visceral fat accumulation (−) and (+) groups, indicating that considerable patients with visceral fat accumulation had weak grip strength in spite of fair skeletal muscle mass. Muscle quality [grip strength (kg)/arm muscle mass (kg)] was significantly lower in patients with visceral fat accumulation. Multiple regression analysis identified eVFA, MCV and sex as significant and independent determinants of muscle quality. In visceral fat accumulation (+) group, the patients with low muscle quality had longer duration of diabetes, lower eGFR, higher serum adiponectin, lower MCV and higher prevalence of cardiovascular diseases, compared to the patients with high muscle quality. Finally, sex- and age-adjusted models showed significant association between low muscle quality and cardiovascular diseases in all subjects (odds ratio 2.28, p = 0.012), especially in patients with visceral fat accumulation (odds ratio 2.72, p = 0.018).ConclusionsT2DM patients with visceral fat accumulation had low muscle quality, and patients with low muscle quality were more affected with cardiovascular diseases.

[1]  T. Funahashi,et al.  Impact of visceral fat on gene expression profile in peripheral blood cells in obese Japanese subjects , 2016, Cardiovascular Diabetology.

[2]  T. Funahashi,et al.  Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice. , 2015, Endocrinology.

[3]  Clifford Goodman,et al.  American Academy of Physical Medicine and Rehabilitation , 1988 .

[4]  Jose M Garcia,et al.  Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review , 2014, Gerontology.

[5]  W. Hiatt,et al.  Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.

[6]  岡内 幸義.  Reduction of Visceral Fat Is Associated With Decrease in the Number of Metabolic Risk Factors in Japanese Men , 2008 .

[7]  Hisashi Yamanaka,et al.  Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition , 2011, Nucleosides, nucleotides & nucleic acids.

[8]  E. Stålberg,et al.  Motor nerve conduction studies: measurement principles and interpretation of findings. , 1995, Journal of clinical neurophysiology.

[9]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[10]  J. Adam,et al.  Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. , 2013, Journal of the American Medical Directors Association.

[11]  V. Mohan,et al.  The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes. , 2013, Diabetes technology & therapeutics.

[12]  Weiping Jia,et al.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.

[13]  T. Funahashi,et al.  Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes. , 2011, Atherosclerosis.

[14]  P Zimmet,et al.  Ethnic comparisons of the cross‐sectional relationships between measures of body size with diabetes and hypertension , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[15]  S. Bandinelli,et al.  Dynapenic Abdominal Obesity as a Predictor of Worsening Disability, Hospitalization, and Mortality in Older Adults: Results From the InCHIANTI Study , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.

[16]  E. Oda.  New criteria for 'obesity disease' in Japan. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[17]  T. Yoshimoto,et al.  Is visceral adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes? , 2016, Cardiovascular Diabetology.

[18]  J. Pell,et al.  Associations Between Diabetes and Both Cardiovascular Disease and All-Cause Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a Prospective Population-Based Cohort Study , 2017, Diabetes Care.

[19]  Makoto Nishida,et al.  A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. , 2005, Diabetes care.

[20]  Taotao Wang,et al.  Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly , 2016, Scientific Reports.

[21]  Y. Hwang,et al.  The ratio of skeletal muscle mass to visceral fat area is a main determinant linking circulating irisin to metabolic phenotype , 2016, Cardiovascular Diabetology.

[22]  [Evidence-based practice guideline for the treatment of CKD]. , 2009, Nihon Jinzo Gakkai shi.

[23]  Evidence-based Practice Guideline for the Treatment of CKD , 2009, Clinical and Experimental Nephrology.

[24]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[25]  Jeffrey R Stout,et al.  Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.

[26]  E. Kang,et al.  Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008–2011) , 2017, Cardiovascular Diabetology.

[27]  H. Makizako,et al.  Using two different algorithms to determine the prevalence of sarcopenia , 2014, Geriatrics & gerontology international.

[28]  L. Ferrucci,et al.  Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  Kozo Nakamura,et al.  Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys , 2016, Osteoporosis International.

[30]  Emile R Mohler,et al.  Peripheral arterial disease: identification and implications. , 2003, Archives of internal medicine.

[31]  J. Després,et al.  Effects of Diet and Physical Activity on Adiposity and Body Fat Distribution: Implications for the Prevention of Cardiovascular Disease , 1993, Nutrition Research Reviews.

[32]  H. Kaneto,et al.  Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. , 2009, Atherosclerosis.

[33]  P. Scherer,et al.  Targeting adipose tissue in the treatment of obesity-associated diabetes , 2016, Nature Reviews Drug Discovery.

[34]  A. Newman,et al.  Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  S. Bandinelli,et al.  Sarcopenic obesity and inflammation in the InCHIANTI study. , 2007, Journal of applied physiology.

[36]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[37]  M. Sargin,et al.  Relation of Muscle Indices with Metabolic Parameters and C-Peptide in Type 2 Diabetes Mellitus. , 2017, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[38]  M. Floeter,et al.  Practice parameter: Electrodiagnostic studies in carpal tunnel syndrome: Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation , 2002, Neurology.

[39]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[40]  T. Yoshimoto,et al.  Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes , 2018, Diabetes/metabolism research and reviews.

[41]  L. Peng,et al.  Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. , 2014, Journal of the American Medical Directors Association.

[42]  E. Stålberg,et al.  Association of muscle strength and electrophysiological measures of reinnervation in diabetic neuropathy , 1998, Muscle & nerve.

[43]  Khalid Yusoff,et al.  Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study , 2015, The Lancet.

[44]  M. Malavolti,et al.  Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years , 2003, Annals of human biology.

[45]  I. Kanazawa,et al.  Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus. , 2016, Diabetes research and clinical practice.

[46]  J. Baeyens,et al.  European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people , 2010 .

[47]  L. Kuller,et al.  Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes , 2009, Diabetes Care.

[48]  Ho-Young Son,et al.  Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.

[49]  Eiji Oda,et al.  New criteria for 'obesity disease' in Japan. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[50]  T. Funahashi,et al.  The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. , 2011, Journal of atherosclerosis and thrombosis.

[51]  T. Funahashi,et al.  Relationship between visceral fat accumulation and urinary albumin-creatinine ratio in middle-aged Japanese men. , 2010, Atherosclerosis.

[52]  S. Bandinelli,et al.  Insulin resistance and muscle strength in older persons. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[53]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[54]  A. Newman,et al.  Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes , 2006, Diabetes.

[55]  C. Ogden,et al.  Associations of Relative Handgrip Strength and Cardiovascular Disease Biomarkers in U.S. Adults, 2011-2012. , 2016, American journal of preventive medicine.

[56]  L. Kuller,et al.  Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes , 2007, Diabetes Care.